Table 67Summary evidence profile for olanzapine versus placebo (tolerability and acceptability data)

Leaving treatment earlyLeaving treatment early because of side effectsN reporting side effectsWeight
Clinician- rated effect sizeRD (random effects) = −0.01 (−0.16, 0.14) 39% versus 40%RD (random effects) = 0.01 (−0.09, 0.1) 8% versus 11%RD (random effects) = 0.1 (−0.05, 0.25) 64% versus 54%WMD = 2.96 (2.37, 3.55)
Quality of evidenceVery lowVery lowVery lowModerate
Number of studies/participants(K = 4; n = 833)(K = 4; n = 833)(K = 2; n = 488)(K = 4; n = 668)
Forest plotPharm 15.03Pharm 16.03Pharm 17.03Pharm 18.02

From: 6, PHARMACOLOGICAL AND OTHER PHYSICAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.